Risk of Suicidal Ideation and Behavior Following Early-Onset Idiopathic Restless Legs Syndrome Treatment.
Willis–Ekbom disease
dopamine agonists
gabapentinoids
idiopathic
restless legs syndrome
self‐injurious behavior
suicidal ideation
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
revised:
15
05
2024
received:
29
01
2024
accepted:
28
05
2024
medline:
5
8
2024
pubmed:
5
8
2024
entrez:
5
8
2024
Statut:
ppublish
Résumé
To estimate incidence rates of suicidal ideation and behavior following treatment initiation with gabapentinoids or dopamine agonists (DAs) in patients with newly diagnosed early-onset idiopathic restless legs syndrome (RLS) and to examine suicidal behavior risk, comparing between those receiving gabapentinoids and DAs. A new user retrospective cohort study using MarketScan claims data from 2012 to 2019 was conducted. Exposures were monotherapy gabapentinoids or DAs initiated within 60 days of new RLS diagnosis. Three varying outcome measures of suicidality were examined and incidence rates were calculated for each. A log-binomial regression model the estimated relative risk (RR) of the outcomes with gabapentinoids. Propensity score weighting adjusted for baseline covariates, including age, substance use disorders, hyperlipidemia, antipsychotic use, hypnotic/sedative use, and mood stabilizer use, which were most imbalanced before weighting. The cohort included 6672 patients, with 4986 (74.7%) initiating a DA and 1686 (25.3%) initiating a gabapentinoid. Incidence rates for all outcome measures were higher in the gabapentinoid group (suicidality: 21.6 vs. 10.7 per 1000 person-years; suicidality with self-harm: 23.0 vs. 11.1 per 1000 person-years; overdose- and suicide-related events: 30.0 vs. 15.5 person-years). Associated risk of suicidality (adjusted RR, 1.27 [95% CI, 0.86-1.88]); suicidality with self-harm (adjusted RR, 1.30 [95% CI, 0.89-1.90]); or overdose- and suicide-related events (adjusted RR, 1.30 [95% CI, 0.93-1.80]) was not significant with gabapentinoids. Incidence rates for suicidal ideation and behavior were higher among the gabapentinoid group, although increased risk was not detected after adjustment. A possible signal cannot be ruled out given limitations of the data and rarity of the outcome.
Substances chimiques
Gabapentin
6CW7F3G59X
Dopamine Agonists
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e5852Subventions
Organisme : NIMH NIH HHS
ID : R36MH127826
Pays : United States
Organisme : NIMH NIH HHS
ID : T32MH125792
Pays : United States
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
W. Ondo, “Clinical Features and Diagnosis of Restless Legs Syndrome and Periodic Limb Movement Disorder in Adults,” in UpToDate, ed. T. W. Post (Waltham, MA: UpToDate, 2023).
E. H. During and J. W. Winkelman, “Drug Treatment of Restless Legs Syndrome in Older Adults,” Drugs & Aging 36, no. 10 (2019): 939–946, https://doi.org/10.1007/s40266‐019‐00698‐1.
P. Yeh, A. S. Walters, and J. W. Tsuang, “Restless Legs Syndrome: A Comprehensive Overview on Its Epidemiology, Risk Factors, and Treatment,” Sleep & Breathing 16, no. 4 (2012): 987–1007, https://doi.org/10.1007/s11325‐011‐0606‐x.
M. H. Silber, M. J. Buchfuhrer, C. J. Earley, B. B. Koo, M. Manconi, and J. W. Winkelman, “The Management of Restless Legs Syndrome: An Updated Algorithm,” Mayo Clinic Proceedings 96, no. 7 (2021): 1921–1937, https://doi.org/10.1016/j.mayocp.2020.12.026.
D. L. Picchietti, S. K. Van Den Eeden, Y. Inoue, and K. Berger, “Achievements, Challenges, and Future Perspectives of Epidemiologic Research in Restless Legs Syndrome (RLS),” Sleep Medicine 31 (2017): 3–9, https://doi.org/10.1016/j.sleep.2016.06.007.
L. DelRosso and O. Bruni, “Treatment of Pediatric Restless Legs Syndrome,” Advances in Pharmacology 84 (2019): 237–253, https://doi.org/10.1016/bs.apha.2018.11.001.
M. H. Silber, “Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder in Adults,” in UpToDate, ed. T. W. Post (Waltham, MA: UpToDate, 2020).
B. Costales, S. M. Vouri, J. D. Brown, B. Setlow, and A. J. Goodin, “Treatment Initiation and Utilization Patterns of Pharmacotherapies for Early‐Onset Idiopathic Restless Legs Syndrome,” Sleep Medicine 96 (2022): 70–78, https://doi.org/10.1016/j.sleep.2022.05.003.
J. W. Winkelman, M. J. Armstrong, R. P. Allen, et al., “Practice Guideline Summary: Treatment of Restless Legs Syndrome in Adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology,” Neurology 87, no. 24 (2016): 2585–2593, https://doi.org/10.1212/WNL.0000000000003388.
D. Garcia‐Borreguero, M. H. Silber, J. W. Winkelman, et al., “Guidelines for the First‐Line Treatment of Restless Legs Syndrome/Willis–Ekbom Disease, Prevention and Treatment of Dopaminergic Augmentation: A Combined Task Force of the IRLSSG, EURLSSG, and the RLS‐Foundation,” Sleep Medicine 21 (2016): 1–11, https://doi.org/10.1016/j.sleep.2016.01.017.
National Vital Statistics System, CDC WONDER Online Database, “Multiple Cause of Death Files, 2018–2022, as Compiled From Data Provided by the 57 Vital Statistics Jurisdictions Through the Vital Statistics Cooperative Program,” 2024, http://wonder.cdc.gov/mcd‐icd10‐expanded.html.
K. S. Para, C. A. Chow, K. Nalamada, et al., “Suicidal Thought and Behavior in Individuals With Restless Legs Syndrome,” Sleep Medicine 54 (2019): 1–7, https://doi.org/10.1016/j.sleep.2018.09.019.
C. J. Earley and M. H. Silber, “Restless Legs Syndrome: Understanding Its Consequences and the Need for Better Treatment,” Sleep Medicine 11, no. 9 (2010): 807–815, https://doi.org/10.1016/j.sleep.2010.07.007.
M. H. Silber, P. M. Becker, C. Earley, D. Garcia‐Borreguero, and W. G. Ondo, “Willis–Ekbom Disease Foundation Revised Consensus Statement on the Management of Restless Legs Syndrome,” Mayo Clinic Proceedings 88, no. 9 (2013): 977–986, https://doi.org/10.1016/j.mayocp.2013.06.016.
S. Zhuang, M. Na, J. W. Winkelman, et al., “Association of Restless Legs Syndrome With Risk of Suicide and Self‐Harm,” JAMA Network Open 2, no. 8 (2019): e199966, https://doi.org/10.1001/jamanetworkopen.2019.9966.
M. Grall‐Bronnec, C. Victorri‐Vigneau, Y. Donnio, et al., “Dopamine Agonists and Impulse Control Disorders: A Complex Association,” Drug Safety 41, no. 1 (2018): 19–75, https://doi.org/10.1007/s40264‐017‐0590‐6.
U. Kallweit, E. Werth, A. Seiz, et al., “Psychiatric Comorbidities in Restless Legs Syndrome,” Journal of Neuropsychiatry and Clinical Neurosciences 28, no. 3 (2016): 239–242, https://doi.org/10.1176/appi.neuropsych.15030055.
Food and Drug Administration (FDA), HORIZANT (Gabapentin Enacarbil) Extended‐Release Tablets for Oral Use [Package Insert] (Atlanta, GA: Arbor Pharmaceuticals, LLC, 2020), https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022399s010lbl.pdf.
Food and Drug Administration (FDA), NEURONTIN® (Gabapentin) Capsules, for Oral Use [Package Insert] (New York, NY: Parke‐Davis, 2020), 1–37, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020235s069,020882s050,021129s050lbl.pdf.
Food and Drug Administration (FDA), LYRICA (Pregabalin) Capsules [Package Insert] (New York, NY: Parke‐Davis, 2020), https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021446s040,%20022488s017lbl.pdf.
Y. Molero, H. Larsson, B. M. D'Onofrio, D. J. Sharp, and S. Fazel, “Associations Between Gabapentinoids and Suicidal Behaviour, Unintentional Overdoses, Injuries, Road Traffic Incidents, and Violent Crime: Population Based Cohort Study in Sweden,” British Medical Journal 365 (2019): I2147, https://doi.org/10.1136/bmj.l2147.
M. A. King, “Pregabalin and Gabapentin Associated With Depression and Suicidal Ideation,” British Medical Journal 363 (2018): k4979, https://doi.org/10.1136/bmj.k4979.
“Medicaid NADAC (National Average Drug Acquisition Cost) Database,” 2022, https://data.medicaid.gov/dataset/dfa2ab14‐06c2‐457a‐9e36‐5cb6d80f8d93.
Food and Drug Administration (FDA), “FDA Approves First Generics of Lyrica,” 2019, https://www.fda.gov/news‐events/press‐announcements/fda‐approves‐first‐generics‐lyrica.
B. Costales, S. M. Vouri, J. D. Brown, B. Setlow, and A. J. Goodin, “Incident Mental Health Episodes After Initiation of Gabapentinoids Vs. Dopamine Agonists for Early‐Onset Idiopathic Restless Legs Syndrome,” Psychiatry Research 328 (2023): 115479, https://doi.org/10.1016/j.psychres.2023.115479.
C. Hankin, D. Lee, D. Garcia‐Borreguero, and Z. Wang, “Increased Risk for New‐Onset Psychiatric Adverse Events in Patients With Newly Diagnosed Primary Restless Legs Syndrome Who Initiate Treatment With Dopamine Agonists: A Large‐Scale Retrospective Claims Matched‐Cohort Analysis,” Journal of Clinical Sleep Medicine 15, no. 09 (2019): 1225–1232, https://doi.org/10.5664/jcsm.7908.
R. P. Allen, M. Bharmal, and M. Calloway, “Prevalence and Disease Burden of Primary Restless Legs Syndrome: Results of a General Population Survey in the United States,” Movement Disorders 26, no. 1 (2011): 114–120, https://doi.org/10.1002/mds.23430.
D. Narowska, M. Bożek, K. Krysiak, et al., “Frequent Difficulties in the Treatment of Restless Legs Syndrome—Case Report and Literature Review,” Psychiatria Polska 49, no. 5 (2015): 921–930, https://doi.org/10.12740/PP/35395.
M. Etminan, M. Sodhi, A. Samii, R. M. Procyshyn, M. Guo, and B. C. Carleton, “Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study,” Journal of Clinical Psychopharmacology 37, no. 1 (2017): 102–104, https://doi.org/10.1097/JCP.0000000000000634.
M. Sodhi, M. Etminan, B. Carleton, and A. Samii, “Risk of Pathological Gambling and Impulse Control Disorders With Dopamine Agonists: A Retrospective Cohort Study,” Journal of Clinical Psychopharmacology 39, no. 6 (2019): 675–676, https://doi.org/10.1097/JCP.0000000000001122.
E. M. Oliva, T. Bowe, S. Tavakoli, et al., “Development and Applications of the Veterans Health Administration's Stratification Tool for Opioid Risk Mitigation (STORM) to Improve Opioid Safety and Prevent Overdose and Suicide,” Psychological Services 14, no. 1 (2017): 34–49, https://doi.org/10.1037/ser0000099.
J. D. Ribeiro, J. C. Franklin, K. R. Fox, et al., “Self‐Injurious Thoughts and Behaviors as Risk Factors for Future Suicide Ideation, Attempts, and Death: A Meta‐Analysis of Longitudinal Studies,” Psychological Medicine 46, no. 2 (2016): 225–236, https://doi.org/10.1017/s0033291715001804.
T. Schmutte, M. Olfson, M. Xie, and S. C. Marcus, “Self‐Harm, Suicidal Ideation, and Attempted Suicide in Older Adults: A National Study of Emergency Department Visits and Follow‐Up Care,” American Journal of Geriatric Psychiatry 28, no. 6 (2020): 646–658.
M. A. Brookhart, R. Wyss, J. B. Layton, and T. Stürmer, “Propensity Score Methods for Confounding Control in Nonexperimental Research,” Circulation. Cardiovascular Quality and Outcomes 6, no. 5 (2013): 604–611, https://doi.org/10.1161/CIRCOUTCOMES.113.000359.
E. A. Stuart, B. K. Lee, and F. P. Leacy, “Prognostic Score‐Based Balance Measures Can Be a Useful Diagnostic for Propensity Score Methods in Comparative Effectiveness Research,” Journal of Clinical Epidemiology 66, no. Suppl. 8 (2013): S84–S90.e1, https://doi.org/10.1016/j.jclinepi.2013.01.013.
J. Chaiard and T. E. Weaver, “Update on Research and Practices in Major Sleep Disorders: Part II—Insomnia, Willis–Ekbom Disease (Restless Leg Syndrome), and Narcolepsy,” Journal of Nursing Scholarship 51, no. 6 (2019): 624–633, https://doi.org/10.1111/jnu.12515.
J. R. Cornelius, M. Tippmann‐Peikert, N. L. Slocumb, C. F. Frerichs, and M. H. Silber, “Impulse Control Disorders With the Use of Dopaminergic Agents in Restless Legs Syndrome: A Case–Control Study,” Sleep 33, no. 1 (2010): 81–87, https://doi.org/10.1093/sleep/33.1.81.
J. Brüdern, N. Hallensleben, I. Höller, et al., “Sleep Disturbances Predict Active Suicidal Ideation the Next Day: An Ecological Momentary Assessment Study,” BioMed Central Psychiatry 22, no. 1 (2022): 65, https://doi.org/10.1186/s12888‐022‐03716‐6.
J. Winkelmann, M. Prager, R. Lieb, et al., “‘Anxietas Tibiarum.’ Depression and Anxiety Disorders in Patients With Restless Legs Syndrome,” Journal of Neurology 252, no. 1 (2005): 67–71, https://doi.org/10.1007/s00415‐005‐0604‐7.
F. Talih, J. Ajaltouni, and F. Kobeissy, “Restless Leg Syndrome in Hospitalized Psychiatric Patients in Lebanon: A Pilot Study,” Neuropsychiatric Disease and Treatment 12 (2016): 2581–2586, https://doi.org/10.2147/NDT.S116271.
S. Chenini, L. Barateau, L. Guiraud, et al., “Depressive Symptoms and Suicidal Thoughts in Restless Legs Syndrome,” Movement Disorders 37, no. 4 (2022): 812–825, https://doi.org/10.1002/mds.28903.
E. Mentari, A. Hughes, J. Feeney, M. Stone, and J. Ware, Statistical Review and Evaluation Antiepileptic Drugs and Suicdality (Silver Spring, MD: Food and Drug Administration, Center for Drug Evalution and Research, Office of Translational Sciences: Office of Biostatistics, 2008), https://www.epilepsy‐society.org.au/downloads/2008‐SuicideandAEDs‐FDA.pdf.
W. M. Leith, W. E. Lambert, J. K. Boehnlein, and M. D. Freeman, “The Association Between Gabapentin and Suicidality in Bipolar Patients,” International Clinical Psychopharmacology 34, no. 1 (2019): 27–32, https://doi.org/10.1097/YIC.0000000000000242.
D. C. Hesdorffer, A. T. Berg, and A. M. Kanner, “An Update on Antiepileptic Drugs and Suicide: Are There Definitive Answers Yet?” Epilepsy Currents 10, no. 6 (2010): 137–145, https://doi.org/10.1111/j.1535‐7511.2010.01382.x.
R. N. Aurora, D. A. Kristo, S. R. Bista, et al., “The Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder in Adults—An Update for 2012: Practice Parameters With an Evidence‐Based Systematic Review and Meta‐Analyses: An American Academy of Sleep Medicine Clinical Practice Guideline,” Sleep 35, no. 8 (2012), 1039–1062, https://doi.org/10.5665/sleep.1988.
S. T. Callahan, D. C. Fuchs, R. C. Shelton, et al., “Identifying Suicidal Behavior Among Adolescents Using Administrative Claims Data,” Pharmacoepidemiology and Drug Safety 22, no. 7 (2013): 769–775, https://doi.org/10.1002/pds.3421.
B. Stanley, G. W. Currier, M. Chesin, et al., “Suicidal Behavior and Non‐Suicidal Self‐Injury in Emergency Departments Underestimated by Administrative Claims Data,” Crisis 39, no. 5 (2018): 318–325, https://doi.org/10.1027/0227‐5910/a000499.
R. S. Swain, L. G. Taylor, E. R. Braver, W. Liu, S. P. Pinheiro, and A. D. Mosholder, “A Systematic Review of Validated Suicide Outcome Classification in Observational Studies,” International Journal of Epidemiology 48, no. 5 (2019): 1636–1649, https://doi.org/10.1093/ije/dyz038.